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Abstract
Background: Several stromal cell subtypes including macrophages contribute to tumor progression by inducing
epithelial-mesenchymal transition (EMT) at the invasive front, a mechanism also linked to metastasis. Tumor
associated macrophages (TAM) reside mainly at the invasive front but they also infiltrate tumors and in this process
they mainly assume a tumor promoting phenotype. In this study, we asked if TAMs also regulate EMT
intratumorally. We found that TAMs through TGF-b signaling and activation of the b-catenin pathway can induce
EMT in intratumoral cancer cells.
Methods: We depleted macrophages in F9-teratocarcinoma bearing mice using clodronate-liposomes and analyzed
the tumors for correlations between gene and protein expression of EMT-associated and macrophage markers. The
functional relationship between TAMs and EMT was characterized in vitro in the murine F9 and mammary gland
NMuMG cells, using a conditioned medium culture approach. The clinical relevance of our findings was evaluated on a
tissue microarray cohort representing 491 patients with non-small cell lung cancer (NSCLC).
Results: Gene expression analysis of F9-teratocarcinomas revealed a positive correlation between TAM-densities
and mesenchymal marker expression. Moreover, immunohistochemistry showed that TAMs cluster with EMT
phenotype cells in the tumors. In vitro, long term exposure of F9-and NMuMG-cells to macrophage-conditioned
medium led to decreased expression of the epithelial adhesion protein E-cadherin, activation of the EMT-mediating
b-catenin pathway, increased expression of mesenchymal markers and an invasive phenotype. In a candidate
based screen, macrophage-derived TGF-b was identified as the main inducer of this EMT-associated phenotype.
Lastly, immunohistochemical analysis of NSCLC patient samples identified a positive correlation between
intratumoral macrophage densities, EMT markers, intraepithelial TGF-b levels and tumor grade.
Conclusions: Data presented here identify a novel role for macrophages in EMT-promoted tumor progression. The
observation that TAMs cluster with intra-epithelial fibroblastoid cells suggests that the role of macrophages in
tumor-EMT extends beyond the invasive front. As macrophage infiltration and pronounced EMT tumor phenotype
correlate with increased grade in NSCLC patients, we propose that TAMs also promote tumor progression by
inducing EMT locally in tumors.
Keywords: Tumor-associated macrophages (TAMs), Macrophage depletion, Clodronate liposomes, Tumor progres-
sion, Tumor invasion, Epithelial-mesenchymal transition (EMT), TGF-b?β?
Background
The malignant potential of solid tumors highly depends
on adjacent stromal cells such as cancer associated
fibroblasts (CAFs), mesenchymal stem cells (MSCs) and
immune cells [1-4]. Macrophages belong to the latter,
and their migration from the stroma into tumors corre-
lates inversely with patient survival in many cancers,
among others breast, lung and thyroid carcinoma as
well as Hodgkin’s lymphoma [5-9]. These correlations
have largely been related to the macrophage secretome
which involves factors that stimulate tumor cell prolif-
eration and survival, angiogenesis and release of pro-
teases essential for extracellular matrix (ECM)
remodeling [10-12]. Vice versa, several paracrine
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signaling loops have been identified through which
macrophages orchestrate invasion of tumor epithelia
into its own newly formed desmoplastic stroma [13-18].
An important step in tumor progression is the acquisi-
tion of invasive properties by tumor cells. EMT is a well
characterized mechanism, through which epithelial cells
trans-differentiate and acquire an invasive mesenchymal
phenotype [19,20]. EMT has recently been recognized
for its involvement in disease progression and the
mechanisms have been linked to metastasis and to the
generation of cancer stem cell-like cells [21-25]. Concor-
dantly, we have previously identified strong correlations
between EMT-associated marker expression in non-
small cell lung cancer (NSCLC) patients and various
clinico-pathologic parameters of tumor progression,
such as size and decreased survival [26].
As EMT represents a crucial step in disease progres-
sion it is of importance to identify and characterize the
mechanisms regulating this process. Whereas it is well
established that the stroma hosts cytokines, growth
factors and enzymes that can induce EMT, the sources
of these factors remain to be fully indentified [27-36].
CAFs, MSCs and Th2 polarized CD4+/CD8+ T-lym-
phocytes have all been shown to contribute to EMT at
the tumor-stroma interface [37-41]. Pro inflammatory
macrophages (classically activated or M1) have likewise
been shown to induce EMT at the invasive front
mainly through TNF-a mediated stabilization of Snail,
a key mediator and marker of EMT [21,42]. Interest-
ingly, M1 TAM induced EMT in tumor cells located at
the invasive front correlates with metastatic disease in
a murine breast cancer model which underscores the
importance of both EMT and macrophages in disease
progression [21].
In this study we asked if TAMs regulate EMT in
intratumoral epithelial cells, as well at the invasive front.
We used clodronate-liposomes (clodrolip) to deplete
TAMs in F9-teratocarinomas. In combination with
established in vitro culture techniques we identified
alternatively activated M2 macrophages as potent regu-
lators of EMT in F9-tumor cells as well as in the murine
epithelial mammary gland cell line, NMuMG. In a can-
didate screen, we identified macrophage-derived TGF-b
and consecutive activation of the b-catenin pathway as
mechanisms of action. An important aspect of this study
was to evaluate the clinical relevance of TAM-induced
EMT in disease progression. This was addressed in a
NSCLC tissue microarray cohort, which confirmed a
significant correlation between intratumoral macrophage
density, EMT markers, intraepithelial TGF-b levels and
tumor grade. The data presented here identify intratu-
moral macrophages as potent regulators of intraepithe-
lial EMT, adding another level to the importance of
macrophages in EMT and disease progression.
Methods
Antibodies and reagents
Primary antibodies: Anti-rat-E-cadherin, anti-rabbit-b-
actin, anti-mouse-vimentin, anti-rabbit-fibronectin all
from Abcam, Cambrigde, MA; anti-rabbit-b-catenin
(Sigma-Aldrich, St. Louis, MO), CD68-Alexa-488 and
F4/80-Alexa-647 (AbD Serotec, Düsseldorf, Germany)
and anti-mouse-active-b-catenin (Millipore, Billerica,
MA). Secondary antibodies: Goat-anti-rat-IgG-TRITC
(Sigma-Aldrich, St. Louis, MO); chicken-anti-rabbit-
Alexa-594 (Molecular Probes, Carlsbad, CA); biotin-SP-
donkey-anti-rabbit-IgG, biotin-SP-donkey-anti-rat-IgG,
and biotin-SP-donkey-anti-mouse-IgG (Jackson Immu-
noResearch Laboratories, INC, Suffolk, UK). Streptavi-
din-HRP (Biolegends, San Diego, CA) was used to
detect biotin labeled secondary antibodies. Recombinant
TGF-b1 and TGF-b neutralizing antibody was pur-
chased from R&D Biosystems (Minneapolis, MN) and
recombinant EGF was kindly provided by Dr. A. Muel-
ler, IMCR, University of Zürich, Switzerland. LEAF (low
endotoxin azide free) purified mouse IgG1,  isotype
control antibody was obtained from BioLegends (San
Diego, CA). Recombinant IL-4 and IL-13 were from
Biosource (Camarillo, CA).
Cell lines and conditioned media
F9-teratocarcinoma cells (ATCC CRL-1720) were grown
on 0.01% gelatin. NMuMG-cells (CRL-1636) were kindly
provided by Prof. G. Christofori, Center for Biomedicine,
University of Basel, Switzerland. Both cell lines were cul-
tured at 37°C, 5% CO2 in DMEM/10% FBS/0.8% penicil-
lin-streptomycin. RAW264.7 macrophages (Sigma-
Aldrich, St. Louis, MO) were cultured at 37°C, 5% CO2
in RPMI1640/10% FBS/0.8% penicillin-streptomycin/1%
Na-pyruvate (GIBCO, Basel, Switzerland). Conditioned
medium was generated by culturing cells at 80% conflu-
ence in DMEM/10% FBS/0.8% penicillin-streptomycin
for 24 h followed by sterile filtration. RAW264.7 macro-
phages were M2 polarized by culturing in DMEM/10%
FBS plus recombinant IL-4 and IL-13 for 48 h (each 10
ng/ml) as previously described [43].
F9 tumors and macrophage depletion
F9-tumors were generated in female SV129S1 mice
(Charles River, Sulzfeld, Germany) and liposomes were
prepared as previously described [11]. Mice were kept in
standard housing and normal diet at the animal facility
of the University of Zürich. Animal studies were
approved by the Veterinary Department of the Canton
Zürich and performed under license 183/2006 issued to
R.A. Schwendener. The control group (n = 6) received
empty liposomes (100 μl/20 g body weight, i.p.), the test
group (n = 6) clodrolip (1.5 mg clodronate/20 g body
weight, i.p.) starting 6 h post tumor inoculation and
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followed by the same dosage every 3rd day for 20 days.
Tumors subjected to immunohistochemistry and protein
analysis were stored in Hanks salt buffer (GIBCO, Basel,
Switzerland) at -80°C. Tumors subjected to q-PCR were
stored in RNAlater as described by the provider (Qia-
gen, Valencia, CA). Data are shown from two indepen-
dent experiments and non-responders as assayed by q-
PCR of Csfr-1 were excluded from the study unless
otherwise noted.
H&E staining, immunohistochemistry and quantification
of frozen F9 tissue sections
Frozen sections (8 μm) were acetone fixed. The sections
were either stained with haematoxylin and eosin
(DAKO, Glostrup, Denmark) following the providers
protocol or blocked with 1% BSA/TBS prior to immu-
nostaining. For immunohistochemistry, the sections
were incubated with primary and secondary antibodies
overnight at 4°C. Nuclei were stained with DAPI (1 μg/
ml). The sections were mounted with Vectashield (Vec-
tor Labs, Burlingame, CA) and visualized with an Olym-
pus fluorescence microscope (1X81) using the CellR
software (Olympus, Hamburg, Germany). The pictures
were merged in Adobe Photoshop CS4. Macrophage
density was quantitatively estimated by counting the
absolute number of CD68+ and F4/80+ cells and the
total number of DAPI positive cells in defined areas
throughout tumor sections using ImageJ software (NIH,
Bethesda, MD). Quantification and correlation of macro-
phage density and tumor cell expression of EMT-asso-
ciated markers was similarly done in a quantitative
manner, using ImageJ to count the absolute number of
CD68+ and EMT-marker positive cells in defined areas
throughout the tumor sections. The quantifications were
done on 6-10 individual sections from various control
and clodrolip treated tumors sampled from two inde-
pendent experiments.
In vitro induction of EMT and immunofluorescence
analysis of F9-and NMuMG-cells
F9-and NMuMG-cells were cultured on sterile glass
coverslips in F9-CM, N-CM, M-CM +/- LEAF purified
IgG1 control antibody (1 μg/ml) or TGF-b neutralizing
antibody (1 μg/ml), DMEM/10% FBS +/- rEGF (50-100
ng/ml) or +/- rTGF-b1 (2 ng/ml). The medium was
renewed every 24 h. The cells were harvested at the
time points annotated, fixed with 3% formaldehyde,
stained and visualized as described for frozen sections.
In vitro invasion assay
The cells were starved in serum free medium for 6 h
and seeded (100.000 cells/well) in Boyden chambers
(Corning, NY, 8 μm pore size) coated with 50 μl 1%
Matrigel (BD Biosciences, Rockville, MD). F9-CM, N-
CM and M-CM +/-LEAF purified IgG1 control antibody
(1 μg/ml) or +/- TGF-b neutralizing antibody (1 μg/ml)
were used as chemoattractants. The assay was incubated
for 48 h at 37°C, 5% CO2. The relative number of invad-
ing cells was estimated by resazurin live cell detection
using the provider’s protocol (Invitrogen, Carlsbad, CA).
Fold invasion was calculated relative to control
conditions.
TOPFLASH reporter assay
The TOPFLASH reporter assay was established as pre-
viously described [44]. The fold values were calculated
as TOPFLASH/FOPFLASH, where TOPFLASH is the
plasmid expressing luciferase downstream of three wild
type b-catenin/Tcf binding sites, and FOPFLASH is the
plasmid with mutated binding sites. Renilla pRL SV40
was included as transfection control. Luciferase was
detected using the Dual Glo Luciferase detection kit
(Promega, Madison, WI). The cells were transfected two
days prior to luciferase readout using a standard in-
house transfection protocol. Fold changes were calcu-
lated relative to controls.
Western blots
F9-and NMuMG-cells were lysed 1% NP-40, 100 mM
orthovanadate, 100 mM 3-indoleacetic acid (IAA), 100
mM phenylmethylsulfonylfluoride (PMSF) at annotated
time points and snap frozen in liquid nitrogen. Frozen
tumors were cut into small pieces and soaked in lysis
buffer and homogenized using an Ultra Turrax T8
homogenizer (IKA-Werke, Staufen, Germany). Protein
concentration was determined by Bradford analysis (Bio-
Rad, Reinach BL, Switzerland). The blots were quanti-
fied using ImageQuant 5.2 software (Amersham Bios-
ciences, Piscataway, NJ). Protein expression was
normalized to b-actin levels.
Quantitative real time PCR
Total RNA was isolated from homogenized F9-tumors
using the RNAeasy kit (Qiagen, Valencia, CA). cDNA
was synthesized using the Omniscript reverse tran-
scriptase kit (Qiagen, Valencia, CA). Q-PCRs were car-
ried out using the LightCycler 480 instrument (Roche
Diagnostics, Rotkreuz, Switzerland). PCR program: 95°
C, 5 min, 45 cycles of 10 s 95°C, 25 s annealing and 15
s 72°C. Primers were obtained from Microsynth, Swit-
zerland, (for primer sequences and annealing tempera-
tures, see Additional file 1: Table S1). The quality of
the PCR-products was assayed on 1.5% agarose gels.
Expression of all target genes was normalized to b-
actin and GAPDH. All samples were run in duplicates;
n = 5-6/per group. Fold change was calculated as clo-
drolip treated versus control tumors using the Pfaffl
equation [45].
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NSCLC tissue microarrays and patient cohort
The selection of NSCLC patient tissue samples and man-
ufacture of the tissue microarrays (TMAs) were done as
previously described [26]. In brief, formalin-fixed and
paraffin-embedded tumor tissues of 532 NSCLC patients
were reviewed by two pathologists and two representative
tissue cores (0.6 mm) were assembled into 3 TMAs.
Patients having obtained neo-adjuvant chemotherapy
were excluded. Sarcomatoid carcinomas were excluded
from this study and EMT was strictly defined by expres-
sion of EMT-associated protein markers and not by mor-
phology (n final = 491). The study was approved by the
institutional review board of the University Hospital Zür-
ich under reference number StV-29-2009.
NSCLC immunohistochemistry and interpretation
Immunohistochemistry on 4 μm sections from the TMA
blocks was performed using automated immunohisto-
chemistry platforms from either Ventana (Ventana Med-
ical Systems, Tucson, AZ) or Bond (Vision Biosystems,
Melbourne, Australia). Following primary monoclonal
antibodies were used: anti-CD68 (DAKO-Cytomation,
clone PG-M1, 1:50 dilution, Glostrup, Denmark), anti-E-
cadherin (Cell Marque, clone EP700Y, 1:200), anti-b-
catenin (BD Transduction laboratories, clone 14, 1:50,
Lexington, KY), anti-vimentin (DAKO-Cytomation,
1:250), Pab anti-periostin (BioVendor, 1:500, Modrice,
Czech Republic) and anti-TGF-b1 (Santa Cruz, 1:100
dilution). Detection was done using the UltraVIEW-
DAB (Ventana Medical Systems) or the Refine-DAB
(Bond) detection kits, including respective secondary
antibodies. Distinct intra-epithelial CD68+ macrophage
density was quantitatively scored by AKB and by two
pathologists (VT and AS) on a multi-headed microscope
(Zeiss Axioscope 2 MOT) using a four-tiered system: 0
(negative), 1+ (few to some CD68+ macrophages), 2+
(moderate number of CD68+ macrophages), and 3+
(multiple CD68+ macrophages). Membranous b-catenin
(AKB and VT) and membranous E-cadherin (VT and
AS) were evaluated for staining intensity according to a
four-tiered system: 0 (negative, no detectable staining), 1
+ (weak, faint discontinuous membrane staining), 2+
(moderate and continuous membrane staining), 3+
(strong and continuous membrane staining). Cytoplas-
mic b-catenin (AKB and VT), cytoplasmic vimentin
(AKB and AS), cytoplasmic periostin (VT and AS) were
scored due to staining intensity: 0 (negative), 1+ (weak),
2+ (moderate), and 3+ (strong) and TGF-b1 (AKB and
VT) was scored for intraepithelial staining intensity: 0
(negative), 1+ (weak), 2+ (moderate), and 3+ (strong).
Statistical methods and correlation interpretation
The statistical analyses of all in vitro assays were per-
formed using the GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA). All data are reported as mean ±
SEM. The significance levels were evaluated by two
tailed, unpaired t-tests; *P < 0.05, **P < 0.01. The statis-
tical and correlation analyses of the NSCLC tissue sam-
ples were done in SPSS 16.0 for windows (IBM, Somers,
NY) using the Spearmann correlation coefficient as a
readout for degree of correlation with *P < 0.05.
Results
Depletion of TAMs reduces mesenchymal gene
expression in F9-terato-carcinomas
We used clodrolip to deplete macrophages in F9-terato-
carcinoma tumors inoculated subcutaneously in Sv129J
mice. In accordance with previous reports [11] we
observed a significant reduction in tumor growth in
response to treatment over the course of three weeks
(Figure 1A). H&E tissue staining revealed large regions
of necrosis in clodrolip treated tumors. Reduction in
tumor size correlated with a 70-80% decrease in F4/80+
and CD68+ macrophage density (Figure 1B and 1C).
Finally, macrophage depletion was confirmed by gene
expression analysis of CD68 and colony stimulating fac-
tor-1 receptor Csfr-1 (Figure 1D). The tumors were next
evaluated for gene expression of key EMT-markers (Fig-
ure 2A). The tumors evaluated in this study were
selected from two independent depletion experiments.
Non-responders were identified by immunohistochemis-
try and RT-PCR analysis of Csfr-1 and CD68 expression
and excluded from the evaluation. The analysis revealed
a relative reduction in expression of two mesenchymal
markers vimentin (Vim, ~2.5-fold) and N-cadherin
(Cdh2, ~4-fold), whereas expression of the epithelial
marker E-cadherin (Cdh1) was increased ~3-fold in clo-
drolip treated tumors relative to controls. Expression of
the EMT-associated transcription regulators snail
(Snai1) and twist (Twist1), both of which repress E-cad-
herin transcription [46,47] were decreased in clodrolip
treated tumors ~4-fold and ~7-fold, respectively (Figure
2A). A hallmark of EMT is the E-cadherin/N-cadherin
switch [48]. To asses if macrophage depletion correlated
with a shift in cadherin expression in individual tumors,
five tumors from a single depletion experiment were
size matched and analyzed by RT-PCR (Figure 2B). Of
the five clodrolip treated tumors 2 were identified as
non-responders, whereas the remaining three displayed
2-6 fold depletion of macrophages relative to their size
matched control tumors. The relative macrophage den-
sity, as assessed by Csfr-1 gene expression levels, corre-
lated strongly with inverse Cdh1 and Cdh2 expression
which confirms the correlation between macrophage
density and the cadherin switch in the individual sets of
tumors (clodrolip/control). Western blotting confirmed
a relatively high expression level of E-cadherin as well as
its cytoplasmic interaction partner b-catenin in three of
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five clodrolip treated tumors (Figure 2C). The b-catenin
pathway can mediate EMT when transcriptionally active
complexes with TCF/LEF are formed upon dissociation
from the membranous E-cadherin [34,44,49]. Thus, we
examined the levels of active b-catenin in the two
tumor groups using an antibody specifically detecting
the active form of b-catenin dephosphorylated on
Ser37/Thr41. Quantification of the western blot revealed
no obvious difference in the levels of active b-catenin
between the two tumor groups (Figure 2D) suggesting
that the levels of activated b-catenin in total tumor tis-
sues were independent of clodrolip treatment.
Macrophages are known to infiltrate and locate in
clusters rather to being distributed evenly throughout
the tumor tissue. Thus, the tumors were analyzed by
immunohistochemistry for intra-tumoral macrophage
density and expression of EMT markers in adjacent
tumor cells (Figure 2E). This analysis identified local
correlations between tumor cell expression of EMT
markers and intratumoral CD68+ macrophage density.
Figure 1 Clodrolip depletes macrophages in F9-teratocarcinoma bearing mice. (A) Size distribution of control and clodrolip tumors at day 10,
17 and 23 after treatment initiation. (B) Upper panel: HE staining of a control tumor section (left) and a clodrolip treated tumor section (right),
magnification 2.5×. Note the large necrotic center in the clodrolip treated tumor (right panel). Panels: Immunohistochemical analysis of CD68+ (red)
and F4/80+ (green) density in control (left) and clodrolip treated (right) tumors, magnification 10×. Overlay of double-positive macrophages is
shown in orange (lower panel); scale bar = 0.2 mm. Macrophage-rich regions are delineated by white lines. Macrophage magnification of 100 × is
displayed in each picture at the upper right corner; scale bar = 0.02 mm. Nuclei were stained with DAPI (blue). (C) Quantitative analysis of F4/80+
(left) and CD68+ (right) cell density in control and clodrolip treated tumors; n = 3/group, bars: means ± SEM; *P < 0.05, unpaired t-test. (D) Relative
gene expression (mRNA levels) of Cd68 and Csfr-1 in clodrolip treated vs. control tumors; n = 6, bars: means ± SEM.
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Figure 2 Macrophage depletion correlates with reduced mesenchymal marker expression in F9-teratocarcinomas. (A) Relative gene
expression (mRNA levels) of E-cadherin (cdh1), N-cadherin (cdh2), vimentin (vim), Snail and Twist in clodrolip treated vs. control tumors; n = 5-6,
bars: means ± SEM. The tumors analyzed in this experiment were collected from two independent depletion experiments. Non-responders were
excluded. (B) Relative gene expression (mRNA levels) of Csfr-1, E-cadherin (cdh1) and N-cadherin (cdh2) in size matched clodrolip treated vs.
control tumors; n = 5-6, bars: means ± SEM. The tumors analyzed in this figure were collected from a single depletion experiment. The table
shows individual volumes and gene expression levels of paired treated vs. control tumors. (C) Western blot analysis of E-cadherin, total b-catenin
and active b-catenin expression in control and clodrolip treated tumors; n = 5. (D) Quantification of the western blot is shown in Figure C. (E)
Immunofluorescence analysis of CD68+ macrophages (green), E-cadherin (red, left panel), b-catenin (red, mid panel) and fibronectin (red, right
panel) in a macrophage poor area (upper panel, magnification 100×) and in a macrophage rich area (lower panel, magnification 100×) in a
control tumor section (left picture, magnification 10×). The nuclei were stained with DAPI (blue). Scale bar = 0.02 mm. The graphs indicate
correlations between CD68+ density and expression of the annotated EMT markers. Each data point represents analysis of one tumor section; n
= 3-5/group. The linear regression coefficient R is indicated.
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Whereas E-cadherin and b-catenin localized to the
plasma membrane of cells in areas with low CD68+
macrophage densities (Figure 2E, upper panel), expres-
sion of both proteins was compromised and partially
lost in areas with high CD68+ densities (Figure 2E,
lower panel). Conversely, fibronectin expression was
increased in areas with high CD68+ densities. Thus,
intratumoral TAM density correlated locally with a
mesenchymal phenotype in F9-tumors.
M2 macrophages induce EMT and stimulate the invasive
properties of F9-and NMuMG cells in vitro
The functional relationship between M2 macrophages
and induction of tumor cell EMT was further investi-
gated in 2D culture systems. To this end, we pre-stimu-
lated murine RAW264.7 macrophages for 48 h with IL-
4 and IL13 to polarize them to a M2 phenotype [43].
F9-teratocarcinoma [50] and NMuMG-cells [29-32]
were cultured in conditioned medium generated either
by F9-cells (F9-CM), NMuMG-cells (N-CM), or by M2
polarized RAW 264.7 macrophages (M-CM). The cells
were evaluated for morphology and cellular localization
of E-cadherin, b-catenin, vimentin and fibronectin (Fig-
ure 3A, Additional file 2: Figure S1 and data not
shown). Both cell lines displayed an epithelial morphol-
ogy when cultured in F9-CM or N-CM and E-cadherin
and b-catenin localized to the cell membrane. A similar
profile was observed in cells cultured for 24 h in M-
CM. However, after long term culture in M-CM (7 days
for F9-cells, 13 days for NMuMG-cells) the cells
acquired a mesenchymal-like morphology (Figure 3A
right panel, Additional file 2: Figure S1, right panel).
This change in morphology correlated with reduced
expression of E-cadherin and b-catenin and an increase
in active b-catenin levels (Figure 3B, Additional file 2:
Figure S2). Moreover, the immunofluorescence analysis
revealed a time dependent increase in expression of two
mesenchymal markers, vimentin and fibronectin (Figure
3A, Additional file 2: Figure S1). This M-CM induced
mesenchymal phenotype was reversible in F9-cells in a
time dependent manner (Figure 3C and 3D, Additional
file 2: Figure S2A). Upon removal of M-CM followed by
culturing in F9-CM for 7 days, E-cadherin and b-catenin
expression levels gradually increased and the proteins
re-localized to the cell membrane, while the level of
active b-catenin gradually decreased,.
We next tested if b-catenin was transcriptionally
activated upon long term M-CM culturing. For this
purpose we used the TOPFLASH/FOPFLASH reporter
assay [44]. M-CM culturing led to an approximately
2-fold increase in b-catenin dependent luciferase
activity in both cell lines, confirming that b-catenin
became transcriptionally activated upon M-CM treat-
ment (Figure 3E).
A widely accepted physiological consequence of EMT
is tumor cell invasion [19,22-24,31,33]. Thus, the inva-
sive properties of F9-and NMuMG-cells were assessed
in vitro using Matrigel coated transwells. Both cell lines
were slowly invading under non-stimulated conditions
and their invasive properties significantly increased in
response to M-CM (Figure 3F). Collectively, the data
show that M-CM generated by M2 polarized macro-
phages induces mesenchymal trans-differentiation, acti-
vates the b-catenin pathway and increases the invasive
properties of both cell lines.
TGF-b signaling is crucial for M2 macrophage induced
tumor cell EMT
As the F9-and NMuMG cells never were in physical
contact with macrophages we concluded that soluble
factors present in the M-CM were responsible for
induction and regulation of the observed trans-differen-
tiation. To identify the specific signaling molecules
involved in EMT induction, the F9-tumors were evalu-
ated for gene expression of 4 macrophage derived fac-
tors previously associated to EMT and tumor cell
invasion, namely Wnt5a, Tgf-b1, Tgf-b2 and Egf
[16,29-34]. Whereas Wnt5a expression was too low for
detection by q-PCR, decreased levels were found for Egf
(~5-fold), Tgf-b1 (~ 2 fold) and Tgf-b2 (~7-fold) in clo-
drolip treated tumors relative to controls (Figure 4A,
Additional file 2: Figure S3). Again, we used the five size
matched, individual tumors from a single depletion
study to address the correlative relationship between
macrophage infiltration (Csfr-1 levels) and expression of
the growth factors. Whereas Egf levels were down regu-
lated in clodrolip treated tumors independently of Csfr-1
levels, expression of Tgf-b1 and Tgf-b2 correlated posi-
tively with Csfr-1 expression (Figure 4B). Macrophages
are a main source of TGF-b1, whereas TGF-b2 to a
large extent is secreted by tumor cells [51]. We there-
fore tested the cells ability to undergo EMT in response
to recombinant EGF (rEGF, 50 ng/ml) and recombinant
TGF-b1 (rTGF-b1, 2 ng/ml) in cell culture. Both cell
lines responded to rEGF and rTGF-b stimuli by
increased levels of pErk42/44 and phosphorylated tyro-
sine (data not shown). However, only rTGF-b1 induced
mesenchymal trans-differentiation in both cell lines (Fig-
ure 4C, Additional file 2: Figure S4) which correlated
with increased b-catenin/Tcf transcription activity (Fig-
ure 4D). To evaluate the importance of TGF-b in
macrophage induced trans-differentiation, we neutra-
lized TGF-b in M-CM prior to F9-and NMuMG-cell
culturing (Figure 5A, Additional file 2: Figure S5 and
data not shown). Whereas both cell lines underwent a
mesenchymal transition when cultured in M-CM con-
taining a control IgG1 antibody, the cells cultured in M-
CM neutralized for TGF-b maintained an epithelial
Bonde et al. BMC Cancer 2012, 12:35
http://www.biomedcentral.com/1471-2407/12/35
Page 7 of 15
Figure 3 M2 polarized macrophages induce trans-differentiation, activation of the b-catenin pathway and invasion of F9- and NMuMG
cells in vitro. (A) Immunofluorescence of E-cadherin, b-catenin, vimentin and fibronectin expression and cellular localization in F9-cells cultured
in F9-CM or M-CM for 24 h or 7d. Pictures of NMuMG-cells are shown in Additional file 2: Figure S1. Scale bar = 0.02 mm. Proteins are colored
red and nuclei were stained with DAPI (blue). Arrows indicate the location of the annotated protein in cells cultured in M-CM for 7d. (B) Relative
protein expression normalized to b-actin levels (quantified from western blots shown in Additional file 2: Figure S2.) of E-cadherin, total and
active b-catenin in F9-cells (left panels) and NMuMG-cells (right panels) cultured in F9-CM, N-CM or M-CM for 6 h, 24 h, 5d, 7d, and 13d. (C)
Immunofluorescence of E-cadherin and b-catenin expression and cellular localization in F9-cells cultured in M-CM for 7d (left panel), followed by
additional culture in F9-CM for 7d (right panel). Scale bar = 0.02 mm. Proteins are colored red and nuclei were stained with DAPI (blue). Arrows
indicate the location of the annotated protein in cells after 7d culture in F9-CM. (D) Relative protein expression normalized to b-actin levels
(quantified from western blot shown in Additional file 2: Figure S2A) of E-cadherin, total and active b-catenin in F9-cells cultured in M-CM for 7d,
followed by F9-CM for additional 24 h and 7d. (E) Fold luciferase expression (TOPFLASH/FOPFLASH) in F9-cells (left) and NMuMG-cells (right)
after 7d or 13d of culture, respectively, in F9-CM, N-CM or M-CM; n = 7; bar = means ± SEM; *P < 0.05. **P < 0.005, unpaired t-test. (F) Invasion
by F9-cells (n = 8) and NMuMG-cells (n = 3) in response to F9-CM, N-CM or M-CM (48 h, 1% Matrigel) calculated relative to F9-CM or N-CM,
respectively. **P < 0.005, unpaired t-test; bars = means ± SEM.
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morphology and phenotype after 7 and 13 days of cul-
ture, respectively. Concordantly, TGF-b neutralization
abolished M-CM mediated activation of the b-catenin/
Tcf transcription complex (Figure 5B) and decreased the
invasive properties of the cells (Figure 5C). Thus, we
conclude that TGF-b is indispensable for induction of
mesenchymal trans-differentiation by M2 macrophages
in our cell lines.
Figure 4 TGF-b induces trans-differentiation in F9-and NMuMG-cells in vitro. (A) Relative gene expression (mRNA levels) of Egf, Tgf-b1 and
Tgf-b2 in clodrolip treated vs. control tumors; n = 5-6, bars: means ± SEM. (B) Relative gene expression (mRNA levels) of Csfr-1, Egf, Tgf-b1, and
Tgf-b2 in size matched clodrolip treated vs. control tumors; n = 5-6, bars: means ± SEM. The table shows individual volumes and gene
expression levels of paired treated vs. control tumors. The tumors analyzed in this figure were collected from a single depletion experiment. (C)
Immunofluorescence of E-cadherin, b-catenin, vimentin and fibronectin expression and cellular localization in F9-cells cultured in DMEM +/-EGF
(50 ng/ml) and +/- TGF-b1 (2 ng/ml) for 7d. Pictures of NMuMG-cells are shown in Additional file 2: Figure S4. Scale bar = 0.02 mm. Proteins are
colored red and nuclei were stained with DAPI (blue). Arrows indicate the location of the annotated protein in cells cultured in DMEM + rTGF-
b1, 7d. (D) Relative luciferase expression (TOPFLASH/FOPFLASH) in F9-cells (left) and NMuMG-cells (right) after 7d or 13d of culture, in DMEM ±
rEGF (50 ng/ml) or rTGF-b1 (2 ng/ml), respectively.
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Figure 5 M2 macrophages regulate EMT through paracrine TGF-b signaling. (A) Immunofluorescence of E-cadherin, b-catenin, vimentin
and fibronectin expression and cellular localization in F9-cells cultured in F9-CM, M-CM, M-CM neutralized for TGF-b and in M-CM plus an IgG1
control antibody for 7d. Pictures of NMuMG-cells are shown in Additional file 2: Figure S5. Scale bar = 0.02 mm. Proteins are colored red and
nuclei were stained with DAPI (blue). Arrows indicate the location of the annotated protein in cells cultured in M-CM and M-CM + TGF-b
neutralizing antibody for 7d. (B) Relative luciferase expression (TOPFLASH/FOPFLASH) in F9-cells (left) and NMuMG-cells (right) after 7d or 13d of
culture in F9-CM, N-CM, M-CM or M-CM neutralized for TGF-b, respectively; n = 4-7; bar = means ± SEM. *P < 0.05, unpaired t-test. (C) Relative
invasion by F9-cells (left) and NMuMG-cells (right) in response to F9-CM, N-CM, M-CM, M-CM neutralized for TGF-b (TGF-bn), or to M-CM plus an
IgG1 control antibody (48h, 1% Matrigel); n = 3-8. Fold invasion was calculated relative to F9-CM or N-CM. *P < 0.05, **P < 0.005, unpaired t-test,
bar = means ± SEM.
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CD68+ macrophage density correlates with a
mesenchymal tumor cell phenotype, intraepithelial TGF-b
levels and grade in non small cell lung cancer patients
We have previously demonstrated a significant correla-
tion between tumor cell expression of selected EMT-
markers and relevant clinico-pathologic parameters of
tumor progression in NSCLC patients [26]. In this study
we used the same tissue microarray cohort to evaluate
the relationship between intra-tumoral macrophage
infiltration and EMT. Two independent researchers ana-
lyzed 491 NSCLC tissue samples of which 228 were ade-
nocarcinomas (AC), 244 squamous cell carcinomas
(SCC) and 19 adeno-squamous carcinomas (ASQ).
Intra-tumoral macrophage density correlated signifi-
cantly with tumor grade (Spearman correlation, SC >
0.2), but not with other clinico-pathologic parameters of
tumor progression like pT, pN, pM or tumor size
(Table 1). The TMAs were further analyzed for tumor
cell expression of EMT-associated markers and TGF- b
(Table 2 and Figure 6). Membranous E-cadherin and
membranous b-catenin were chosen as epithelial mar-
kers, whereas vimentin, periostin and cytoplasmic b-
catenin were chosen as mesenchymal markers. Both eva-
luations established a moderate, positive correlation
between intratumoral CD68+ macrophage density,
mesenchymal marker expression and TGF-b1 levels in
tumor cells (SC > 0.2). Moreover, CD68+ macrophage
density correlated negatively with membranous b-cate-
nin in both evaluations (SC > -0.2). E-cadherin likewise
showed a modest negative correlation with CD68+
macrophage density in evaluation 1 (SC > -0.2), how-
ever, evaluation 2 could not confirm this correlation.
Finally, expression of EMT markers correlated positively
with tumor grade (SC < 0.2). This data suggests that the
parameter tumor grade is most closely related to
increased amounts of intratumoral macrophages, intrae-
pithelial TGF-b levels and expression of EMT markers.
Discussion
The recognition that disease progression is highly influ-
enced by the tumor microenvironment has lead to the con-
cept that cancer management may be improved by
therapeutic targeting of the tumor stroma [11,52,53]. We
and others have previously demonstrated the potential
therapeutic value of macrophages by showing that their
depletion or inhibition of their recruitment leads to
reduced angiogenesis and tumor growth, increased tumor
necrosis and reduced metastasis in tumor bearing mice
[11,51]. Moreover, M1 macrophages have been shown to
regulate EMT at the invasive front through paracrine TNF-
a signaling and Snail stabilization, linking tumor inflamma-
tion to EMT and metastasis [20,42]. In this study, we show
that the role of tumor associated macrophages in tumor
cell EMT extends beyond the invasive front.
Table 1 Clinico-pathologic parameters and correlation
with CD68+ macrophage tumor infiltration
Tumors No. % CD68+ intra-tumoral TAMs
n = 491 Evaluation 1 Evaluation 2
Histotype
AC 228 46.4
SCC 244 49.7
ASQ 19 3.9
pT
T1 100 20.4 SC 0.000 0.008
T2 268 54.6 p 0.993 0.859
T3 74 15.1
T4
pN
N0 257 52.3 SC -0.022 -0.072
N1 147 29.9 p 0.706 0.116
N2 77 15.7
N3 10 2.0
pM
M0 448 91.2 SC -0.117 -0.006
M1 43 8.8 p 0.082 0.161
Grade
G1 28 5.7 SC 0.227 0.025
G2 253 51.1 p ≤ 0.001* ≤ 0.001*
G3 210 42.8
Size
≤ 3.7 cm 246 50.1 SC 0.072 0.080
> 3.7 cm 245 49.9 p 0.114 0.079
*for G1 and G2 vs. G3
Abbreviations: AC Adenocarcinoma, SCC Squamous Cell Carcinoma, ASQ
Adeno-squamous Carcinoma
p-values and Spearman correlation values (SC) are indicated. Statistical
analysis was done with SPSS 16.0
Table 2 Correlation of EMT-associated protein markers
and TGF-b with CD68+ macrophage tumor infiltration
Proteins CD68+ intratumoral TAMs Grade
Evaluation 1 Evaluation 2 1-3
E-cadherin membrane SC -0.001 -0.073 -0.104
p 0.035 0.111 0.021
b-Catenin membrane SC -0.174 -0.175 -0.190
p ≤ 0.001 ≤ 0.001 ≤ 0.001
b-Catenin cytoplasm SC 0.223 0.231 0.163
p ≤ 0.001 ≤ 0.001 ≤ 0.001
Vimentin cytoplasm SC 0.225 0.485 0.178
p ≤ 0.001 ≤ 0.001 ≤ 0.001
Periostin cytoplasm SC 0.177 0.215 0.112
p ≤ 0.001 ≤ 0.001 0.008
TGF-b intraepithelial SC 0.230 0.184 0.254
p ≤ 0.001 ≤ 0.001 ≤ 0.001
p-values and Spearman correlation values (SC) are indicated. Statistical
analysis was done with SPSS 16.0. Tumors, n = 491
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Gene expression analysis of control and clodrolip trea-
ted tumors revealed a positive correlation between
macrophage infiltration and mesenchymal marker
expression in whole F9-tumors. Moreover, immunohis-
tochemical analysis of the tumors confirmed a positive
correlation between macrophage and mesenchymal
tumor cell density, suggesting that TAMs modulate the
phenotype of tumor cells located in the neighboring
microenvironment. This trend was confirmed in vitro
using a conditioned medium approach to facilitate
trans-differentiation in F9-and NMuMG-cells. As
assayed by immunofluorescence, the mesenchymal phe-
notype was reversible in F9-cells upon M-CM removal
in vitro. Fibroblastoid epithelial cancer cells can re-
acquire epithelial traits by undergoing mesenchymal-
epithelial transition (MET). MET has been assigned with
a hypothetical role in metastatic colony formation where
plastic tumor cells, in response to micro-environmental
changes, reacquire epithelial traits [19,54]. That the M-
CM induced mesenchymal phenotype was reversible in
vitro, suggests that TAMs incite tumor cell plasticity
and contribute to tumor heterogeneity through regula-
tion of EMT/MET. The occurrence of EMT in tumors
may therefore be transient and highly dependent on the
local microenvironment.
The b-catenin pathway is an important mediator of
EMT [19,34]. Although immunoblotting analysis of
whole tumor tissues failed to establish a noticeable dif-
ference in the levels of active b-catenin in the two F9-
tumor groups, in vitro systems utilizing the TOP-
FLASH/FOPFLASH reporter system confirmed a signifi-
cant increase in transcriptional activity in both F9-and
NMuMG cells upon long term M-CM culturing.
Together with the immunohistochemical data, which
indicated that macrophages mainly cluster with cells
expressing biochemical EMT markers locally in the
tumor, we conclude that the levels of active b-catenin in
F9-tumors were too low to be detected by western
Figure 6 Intratumoral CD68+ macrophage density correlates with mesenchymal protein expression in NSCLC patient samples. NSCLC
tissue sections were stained for CD68, E-cadherin, b-catenin and vimentin. NSCLC tumor 1 is an adenocarcinoma of solid subtype, NSCLC tumor
2 is an adenocarcinoma of glandular subtype. NSCLC tumor 1 is a score 2 for CD68, score 1 for membranous E-cadherin, score 2 for
membranous b-catenin, score 3 for cytoplasmic b-catenin and score 3 for vimentin. NSCLC tumor 2 is a score 1 for CD68, score 3 for
membranous E-cadherin, score 3 for membranous b-catenin, score 1 for cytoplasmic b-catenin and score 0 for vimentin. Pictures were acquired
at 20 × magnification. Graphs indicate correlations between intratumoral CD68+ macrophage infiltration and tumor cell expression of the
annotated EMT-associated markers. The regression coefficient R is indicated.
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blotting. Therefore, based on the in vitro data we sug-
gest that M2 macrophages signal EMT in part through
activation of the b-catenin pathways.
In a candidate based screen we identified TAM-
derived TGF-b as the main cytokine inducing EMT in
our assays. TGF-b is a well characterized regulator of
EMT and it can induce epithelial trans-differentiation
through various pathways. On one hand, TGF-b induces
EMT through activation of various intrinsic pathways, e.
g. AKT, SMAD and b-catenin [19,29-32]. Conversely, it
stimulates the production of MMPs which are important
stroma-derived inducers of tumor cell EMT [25,35].
Although being a strong mediator of EMT, TGF-b often
signals in conjunction with other cytokines such as
TNF-a, Wnt and EGF [40,55,56]. We were therefore
surprised by the finding that neutralization of TGF-b in
M-CM was sufficient to abrogate the invasive, mesench-
ymal cell phenotype. Although we cannot exclude syner-
gistic effects between TGF-b and other macrophage-
derived cytokines, we conclude that TGF-b is indispen-
sable for the induction of EMT in our cell systems. All
together, the data suggest a model in which M2 polar-
ized macrophages regulate EMT through TGF-b signal-
ing and consecutive activation of the b-catenin pathway.
This finding challenges the previous finding of M1
macrophages signaling EMT at the invasive front
through paracrine TNF-a signaling and consecutive
SNAIL activation [21,42]. Our findings suggest that the
signaling pathways through which macrophages induce
EMT is highly context dependent.
An important aspect of this study was to address the
clinical relevance of TAM regulated EMT. For this pur-
pose we analyzed tumor samples of NSCLC patients in
which we had previously established significant correla-
tions between tumor cell expression of EMT markers
and disease outcome [26]. In the current study, we eval-
uated the correlation between intra-tumoral CD68+
macrophage density and EMT profile. In concordance
with the murine data, the NSCLC study revealed a posi-
tive, significant correlation between CD68+ macrophage
density, intraepithelial TGF-b levels and expression of
EMT markers in adjacent tumor cells. Moreover, intra-
tumoral CD68+ density, intraepithelial TGF-b1 levels
and EMT tumor profile correlated with high tumor
grade. Although TAMs and tumor cell EMT generally
are associated with metastasis, we did not obtain evi-
dence for such correlation (Table 1) and it is important
to note that the metastatic process is complex and not
exclusively depending on these two factors.
Conclusions
Collectively, the data suggest a model in which TAMs
induce EMT in intratumoral epithelial cells through
paracrine TGF-b signaling and consecutive activation of
the b-catenin pathway. As macrophage infiltration,
TGF-b1 expression and pronounced EMT tumor pheno-
types correlate with increased grade in NSCLC patients,
we propose that TAMs contribute to tumor progression
by inducing mesenchymal trans-differentiation in local
clusters in tumors and thereby contribute to tumor het-
erogeneity and grade. As EMT is associated with both
drug resistance and patient relapse it is attractive to
speculate that therapeutic targeting of tumor associated
macrophages could improve disease outcome.
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